Beyond Monoclonal Gammopathy of Undetermined Significance, Clinical Spectrum of Immunoglobulin M Gammopathy: A Case Series with Focus on the Diagnostic and Management Challenges

References

• FonsecaR, HaymanS. Waldenström macroglobulinaemia. Br. J. Haematol. 138(6), 700–720 (2007).
   PubMed Web of Science ®Google Scholar
• MorraE. Cryoglobulinemia. Hematology Am. Soc. Hematol. Educ. Program 368–372 (2005).
   PubMedGoogle Scholar
• TerrierB, KarrasA, KahnJEet al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore) 92(2), 61–68 (2013).
   PubMed Web of Science ®Google Scholar
• RoccatelloD, SaadounD, Ramos-CasalsMet al. Cryoglobulinaemia. Nat. Rev. Dis. Primers 4(1), 11 (2018).
   PubMedGoogle Scholar
• GhetieD, MehrabanN, SibleyCH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum. Dis. Clin. North Am. 41(1), 93–99 (2015).
   PubMed Web of Science ®Google Scholar
• OlsonN, YerrabothalaS, DunbarN. Successful use of cryocrit for monitoring response to therapeutic plasma exchange in type 1 cryoglobulinemia. J. Clin. Apher. 31(4), 403–404 (2016).
   PubMed Web of Science ®Google Scholar
• SidanaS, RajkumarSV, DispenzieriAet al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am. J. Hematol. 92(7), 668–673 (2017).
   PubMed Web of Science ®Google Scholar
• MuchtarE, MagenH, GertzMA. How I treat cryoglobulinemia. Blood 129(3), 289–298 (2017).
   PubMed Web of Science ®Google Scholar
• FerriC, GrecoF, LongombardoGet al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin. Exp. Rheumatol. 9(6), 621–624 (1991).
   PubMed Web of Science ®Google Scholar
• SeneD, Ghillani-DalbinP, ThibaultVet al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J. Rheumatol. 31(11), 2199–2206 (2004).
   PubMed Web of Science ®Google Scholar
• CastilloJJ, TreonSP. How we manage Bing–Neel syndrome. Br. J. Haematol. 187(3), 277–285 (2019).
   PubMed Web of Science ®Google Scholar
• VarettoniM, DefrancescoI, DiamantiL, MarchioniE, FarinaLM, PichiecchioA. Bing–Neel Syndrome: Illustrative Cases and Comprehensive Review of the Literature. Mediterr. J. Hematol. Infect Dis. 9(1), e2017061 (2017).
   PubMedGoogle Scholar
• MinnemaMC, KimbyE, D’SaSet al. Guideline for the diagnosis, treatment and response criteria for Bing–Neel syndrome. Haematologica 102(1), 43–51 (2017).
   PubMed Web of Science ®Google Scholar
• GavriatopoulouM, Ntanasis-StathopoulosI, MoulopoulosLAet al. Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy: a case report. Medicine (Baltimore) 98(44), e17794 (2019).
   PubMed Web of Science ®Google Scholar
• TreonSP, XuL, YangGet al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N. Engl. J. Med. 367(9), 826–833 (2012).
   PubMed Web of Science ®Google Scholar
• TreonSP, XuL, GuerreraMLet al. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J. Clin. Oncol. 38(11), 1198–1208 (2020).
   PubMed Web of Science ®Google Scholar
• YangG, ZhouY, LiuXet al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 122(7), 1222–1232 (2013).
   PubMed Web of Science ®Google Scholar
• MinzenmayerAN, MirandaRN, PowellPR, ParekhPK. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation. J. Cutan. Pathol. 47(9), 850–853 (2020).
   PubMed Web of Science ®Google Scholar
• AbeykoonJP, PaludoJ, KingRLet al. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. Am. J. Hematol. 93(2), 187–194 (2018).
   PubMed Web of Science ®Google Scholar
• VosJM, GustineJ, RennkeHGet al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br. J. Haematol. 175(4), 623–630 (2016).
   PubMed Web of Science ®Google Scholar
• LindströmFD, HedJ, EneströmS. Renal pathology of Waldenström’s macroglobulinaemia with monoclonal antiglomerular antibodies and nephrotic syndrome. Clin. Exp. Immunol. 41(2), 196–204 (1980).
   PubMed Web of Science ®Google Scholar
• TreonSP, EmmanouilidesC, KimbyEet al. Extended rituximab therapy in Waldenström’s macroglobulinemia. Ann. Oncol. 16(1), 132–138 (2005).
   PubMed Web of Science ®Google Scholar
• KolikkatN, MoideenS, KhaderA, MohammedTP, UvaisNA. Waldenstrom’s Macroglobulinemia: a case report. J. Family Med. Prim. Care 9(3), 1768–1771 (2020).
   PubMedGoogle Scholar
• DimopoulosMA, AnagnostopoulosA, KyrtsonisMCet al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J. Clin. Oncol. 25(22), 3344–3349 (2007).
   PubMed Web of Science ®Google Scholar
• KapoorP, AnsellSM, FonsecaRet al. Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines 2016. JAMA Oncol. 3(9), 1257–1265 (2017).
   PubMed Web of Science ®Google Scholar
• GrunenbergA, BuskeC. Monoclonal IgM gammopathy and Waldenström’s macroglobulinemia. Dtsch. Arztebl. Int. 114(44), 745–751 (2017).
   PubMed Web of Science ®Google Scholar
• KordeN, KristinssonSY, LandgrenO. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 117(21), 5573–5581 (2011).
   PubMed Web of Science ®Google Scholar
• vande Donk NWCJ, PawlynC, YongKL. Multiple myeloma. Lancet 397(10272), 410–427 (2021).
   PubMed Web of Science ®Google Scholar
• GusdorfL, LipskerD. Schnitzler Syndrome: the paradigm of an acquired adult-onset auto-inflammatory disease. G Ital Dermatol. Venereol. 155(5), 567–573 (2020).
   PubMed Web of Science ®Google Scholar
• van LeersumFS, PotjewijdJ, van GeelM, SteijlenPM, VreeburgM. Schnitzler’s syndrome – a novel hypothesis of a shared pathophysiologic mechanism with Waldenström’s disease. Orphanet. J. Rare Dis. 14(1), 151 (2019).
   PubMedGoogle Scholar
• GoodmanAM, CohenPR, LiA, HindsB, KurzrockR. Schnitzler syndrome associated with MYD88 L265P mutation. JAAD Case Rep. 5(4), 312–316 (2019).
   PubMedGoogle Scholar
• LimW, ShumakKH, ReisMet al. Malignant evolution of Schnitzler’s syndrome–chronic urticaria and IgM monoclonal gammopathy: report of a new case and review of the literature. Leuk. Lymphoma 43(1), 181–186 (2002).
   PubMed Web of Science ®Google Scholar
• DecauxO, LauratE, PerlatA, CazaletsC, JegoP, GrosboisB. Systemic manifestations of monoclonal gammopathy. Eur. J. Intern. Med. 20(5), 457–461 (2009).
   PubMed Web of Science ®Google Scholar
• CampagnoloM, ZambelloR, Nobile-OrazioEet al. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. J. Neurol. Neurosurg. Psychiatry 88(12), 1094–1097 (2017).
   PubMed Web of Science ®Google Scholar
• KodairaM, YamamotoK. Rituximab improves subclinical temporal dispersion of distal compound muscle action potential in Anti-MAG/SGPG neuropathy associated with Waldenström macroglobulinemia: a case report. Case Rep. Neurol. 5(1), 34–39 (2013).
   PubMedGoogle Scholar
• UekiS, NakamuraM, SasakiRet al. Beneficial effect of bendamustine in a patient with anti-MAG/SGPG neuropathy and Bing–Neel syndrome associated with Waldenström Macroglobulinemia: a case report. Case Rep. Neurol. 10(1), 88–94 (2018).
   PubMed Web of Science ®Google Scholar
• YangY, CanepaC. IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom’s macroglobulinaemia and medullary carcinoma of the thyroid. BMJ Case Rep. 14(2), e240242 (2021).
   PubMedGoogle Scholar